PharmExec Direct: Having trouble viewing the email? Click Here

In this ISSUE

FDA’s Accelerated Pathways Are the New Normal

Data Unleashed: Cooperation Among Competitors

The Diversity Dearth in Pharma
Legal Affairs
Pressure Builds to Revamp Of-Label Marketing Rules
Growing enthusiasm for value-based purchasing by all components of healthcare speaks to the need for pharma companies to be able to include wider benefits in risk-based analyses of drug use, especially for off-label uses critical to patients.
... /Read more/
Regulatory Affairs
Disclosure D-Day Draws Near In Europe
European pharma is bracing itself for EFPIA’s June deadline requiring the disclosure of transfer-of-value transactions make to HCPs.
... /Read more/
Calendar
/ PCC 2016 – CBI’s 13th Annual Pharmaceutical Compliance Congress /
 
/ IVT’s 17th Computer and Software Validation /
 
/ West Coast Medical Education & Research Grants Breakthrough Summit /
 
/ Managed Access Programs /
 
Pricing & Reimbursement
Raising the Stakes On Value-Based Pricing
The importance of betting on outcomes, not simply risk sharing, when implementing pharma-payer arrangements.
... /Read more/
Pricing & Reimbursement
Europe: What Price Medicines? The Subject That Won't Go Away
The dilemma continues: Which medicines should Europe's health systems pay for – and how much should they pay?
... /Read more/
Opinion
ACP’s Drug Cost Paper Ignores Economic Reality
The American College of Physicians has chimed in on the debate surrounding prescription drug costs, offering its views for stemming the escalation.
... /Read more/

update my profile / advertise with us / print & digital subscribe / visit pharmexec.com